MindWalk Holdings (HYFT)
NASDAQ:HYFT
Top Page
MindWalk Holdings
(NASDAQ:HYFT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-15.25% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance (ongoing losses and significant cash burn) and a weak technical setup (below key moving averages with negative MACD). Offsetting these, the latest earnings call highlighted strong revenue growth and early validation of a shift toward recurring platform revenue, but execution and funding risks remain material.
Positive Factors
Revenue growth and U.S. expansion
Sustained high-single- to double-digit revenue growth and a doubling of U.S. sales signal durable commercial traction and successful geographic expansion. This improves addressable market access and underpins scale economics if growth sustains, supporting longer-term margin and enterprise revenue stability.
Negative Factors
Persistent cash burn and negative cash flow
Consistent operating and free cash outflows create structural funding pressure. With limited internal cash generation, the company remains dependent on external financing or asset-level monetization, increasing dilution risk and constraining the firm’s ability to consistently invest in commercialization and R&D over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and U.S. expansion
Sustained high-single- to double-digit revenue growth and a doubling of U.S. sales signal durable commercial traction and successful geographic expansion. This improves addressable market access and underpins scale economics if growth sustains, supporting longer-term margin and enterprise revenue stability.
Read all positive factors
MindWalk Holdings (HYFT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.92M
Dividend YieldN/A
Average Volume (3M)386.68K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-17.94%
EPS Growth21.43%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding46,711,864
10 Day Avg. Volume187,309
30 Day Avg. Volume386,680
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.83
P/FCF Ratio-2.80
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue3.58
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda-6.14
Forecast
1Y Price Target
$5.00Price Target Upside323.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$16.08M
MindWalk Holdings Business Overview & Revenue Model
Company Description
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, throug...
MindWalk Holdings Earnings Call Summary
Earnings Call Date:Mar 12, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jul 23, 2026
Earnings Call Sentiment Positive
The call presented multiple strong commercial and scientific positives: robust revenue growth (Q3 +52% YoY, nine-month +45%), U.S. revenue doubling, the signing of the first enterprise recurring Lens AI platform contract, important preclinical pipeline discoveries (conserved dengue epitope, influenza conserved feature, GLP-1 activity vs semaglutide), peer-reviewed validation, and a new nanobody platform launch. Offsetting these strengths are higher operating expenses (notably S&M and R&D), a Q3 gross margin dip, ongoing net losses and cash burn ($10.1M YTD), and dependency on pending preclinical readouts and successful asset-level financing. Overall, the highlights—revenue acceleration, platform monetization, and differentiated scientific milestones—materially outweigh the lowlights tied to investment-driven losses and program-stage risk.Positive Updates
Strong Revenue Growth and U.S. Expansion
Q3 revenue of $4.2M, up 52% year over year from $2.7M. Nine-month revenue of $11.4M, up 45% versus $7.9M prior year. U.S. revenue doubled year over year to $2.6M (from $1.3M), reflecting strategic investments in Boston/Cambridge and North American commercial focus.
Negative Updates
Quarterly Gross Margin Compression
Q3 gross margin declined to 59% from 65% in the prior-year quarter (a 6 percentage point drop), attributed to business mix variability despite YTD improvement.
Read all updates
Q3-2026 Updates
Positive
Negative
Strong Revenue Growth and U.S. Expansion
Q3 revenue of $4.2M, up 52% year over year from $2.7M. Nine-month revenue of $11.4M, up 45% versus $7.9M prior year. U.S. revenue doubled year over year to $2.6M (from $1.3M), reflecting strategic investments in Boston/Cambridge and North American commercial focus.
Read all positive updates
Company Guidance
Management guided that recent momentum — Q3 revenue of C$4.2M (up 52% from C$2.7M a year ago), U.S. revenue doubling to C$2.6M from C$1.3M, and nine‑month revenue of C$11.4M (up 45% from C$7.9M) — plus the signing of a one‑year enterprise Lens AI platform contract will shift the mix toward contracted, recurring monthly revenue and, with broader Lens AI adoption, drive margin expansion (Q3 gross margin 59% vs. 65% prior year; nine‑month 58% vs. 53%, +5 ppt); management reaffirmed ongoing investment while noting Q3 R&D of C$1.2M (nine months C$3.5M), sales & marketing of C$1.8M (nine months C$4.3M), G&A of C$3.1M (nine months C$9.5M) with G&A expected to be flat to modestly up, that cash of C$14.2M and YTD operating cash use of C$10.1M provide runway, and that asset‑level financing structures are being developed to monetize pipeline while they expect these investments to yield returns.MindWalk Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.21M | 24.31M | 24.81M | 21.17M | 19.80M | 17.91M |
| Gross Profit | 10.88M | 11.50M | 9.19M | 7.32M | 9.17M | 11.40M |
| EBITDA | -10.62M | -28.89M | -23.22M | -21.55M | -12.27M | -4.60M |
| Net Income | -9.19M | -29.97M | -26.43M | -27.21M | -17.09M | -7.34M |
Balance Sheet | ||||||
| Total Assets | 23.17M | 44.44M | 59.99M | 77.81M | 93.49M | 66.96M |
| Cash, Cash Equivalents and Short-Term Investments | 14.18M | 10.66M | 3.46M | 8.28M | 29.96M | 41.76M |
| Total Debt | 3.55M | 13.40M | 13.68M | 7.27M | 2.77M | 3.46M |
| Total Liabilities | 8.19M | 20.82M | 26.07M | 20.01M | 18.36M | 10.04M |
| Stockholders Equity | 14.98M | 23.63M | 33.92M | 57.80M | 75.28M | 56.92M |
Cash Flow | ||||||
| Free Cash Flow | -11.89M | -7.21M | -5.64M | -21.33M | -11.18M | -2.03M |
| Operating Cash Flow | -11.15M | -6.41M | -4.25M | -19.83M | -9.92M | -600.00K |
| Investing Cash Flow | 12.97M | -799.00K | -1.56M | -1.97M | -5.21M | -2.46M |
| Financing Cash Flow | 201.94K | 14.89M | 1.02M | -621.00K | 2.88M | 43.38M |
MindWalk Holdings Technical Analysis
Neutral
1.18
Price Trends
1.25
Negative
1.61
Negative
1.74
Negative
Market Momentum
-0.05
Negative
49.98
Neutral
51.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYFT, the sentiment is Neutral. The current price of 1.18 is above the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.25, and below the 200-day MA of 1.74, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.98 is Neutral, neither overbought nor oversold. The STOCH value of 51.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HYFT.
MindWalk Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $774.08M | -3.32 | -170.83% | ― | ― | 37.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $71.99M | -0.84 | -59.07% | ― | ― | -58.47% | |
46 Neutral | $50.92M | -6.63 | -63.13% | ― | -17.94% | 21.43% | |
44 Neutral | $44.59M | -0.48 | -122.43% | ― | -100.00% | -8.30% |
* Healthcare Sector Average
HYFT
MindWalk Holdings
1.18
0.77
187.10%
XBIT
XBiotech
2.43
-0.75
-23.58%
RLMD
Relmada Therapeutics
7.19
6.88
2234.42%
PMVP
PMV Pharmaceuticals
1.47
0.43
41.35%
HOWL
Werewolf Therapeutics
0.92
0.06
7.00%
ESLA
Estrella Immunopharma
1.70
0.85
100.00%
MindWalk Holdings Corporate Events
MindWalk Holdings Reports March Insider Share Purchases and RSU Positions
Apr 1, 2026
MindWalk Holdings Corp. voluntarily furnished a Form 6-K on March 31, 2026, summarizing insider trading activity reported on Canada’s SEDI system for the period March 18–27, 2026. The filing is explicitly designated as furnished, not f...
MindWalk Holdings Discloses March Insider Share Purchases in Voluntary U.S. Filing
Mar 23, 2026
MindWalk Holdings on March 23, 2026 voluntarily furnished a Form 6‑K to U.S. regulators summarizing insider activity reported on Canada’s SEDI system for the week ended March 21, 2026. The filing underscores that the firm, a foreign pr...
MindWalk Holdings Delivers Q3 Revenue Surge and Secures First LensAI Platform Contract
Mar 12, 2026
On March 12, 2026, MindWalk Holdings reported Q3 fiscal 2026 results for the period ended January 31, 2026, posting revenue of C$4.2 million, up 52% year over year and marking a third straight quarter of revenue growth, with U.S. sales doubling to...
MindWalk Holdings Files Q3 2026 MD&A and Interim Financials
Mar 12, 2026
MindWalk Holdings Corp. has filed a Form 6-K for March 2026, furnishing its management’s discussion and analysis and condensed interim consolidated financial statements for the three- and nine-month periods ended January 31, 2026 and 2025. T...
MindWalk Unveils B Cell Llama Nanobody Platform Backed by Peer-Reviewed Study
Mar 6, 2026
On March 6, 2026, MindWalk Holdings announced B Cell Llama, a new nanobody discovery platform built to generate llama-derived VHH single-domain antibodies for bispecifics, multispecific therapeutics and CAR-T cell therapies. The system extends its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.